Markulan, L. and Makarevych, L. 2022. Pembrolizumab as an immunotherapy drug in the treatment of a patient with recurrent (unresectable) cancer of the lower lip. General Surgery. 2 (Dec. 2022), 75–82. DOI:https://doi.org/10.30978/GS-2022-2-75.